Mankind Pharma Ltd. Results

H1FY25 & Q2FY25 Result Announced for Mankind Pharma Ltd.

Pharmaceuticals company Mankind Pharma announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from Operations at Rs 3,077 crore, up by 14% YoY. Domestic revenue at Rs 2,796 crore, up by 11% YoY; Exports at Rs 281 crore, up by 57% YoY. Reported EBITDA margin of 27.7% and PAT margin of 21.4%. Diluted EPS of Rs 16.3, up by 30% YoY (FV Re.1). H1FY25 Financial Highlights: Revenue from Operations at Rs 5,970 crore, up by 13% YoY. Domestic revenue at Rs 5,430 crore, up by 10% YoY; Export at Rs 540 crore, up by 59% YoY. Reported EBITDA margin at 25.8%, up by 14% YoY with Adj. EBITDA margin of 26.5% and PAT margin of 20.1%. Diluted EPS of Rs 29.7, up by 20% YoY (FV Re.1). Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma, said: “We are pleased to report steady revenue growth of 13.6% YoY with strong EBITDA margins of 27.7%, driven by recovery in volume, continued outperformance in chronic segment and operating leverage. OTC business has been carved out to a WOS2 of Mankind Pharma. From Q3, this business has embarked on the journey towards its next phase of growth. Our acquisition of BSV perfectly aligns with our vision to expand into a high entry barrier portfolio with the #1 player in the gynaecology segment, leadership in certain critical care products, and further enhance our R&D; capabilities. Multiple growth levers – resilient base business, fast growing specialty chronic segment, high potential OTC business, and high-entry barrier super specialty portfolio of BSV. Together, these levers will propel our growth journey ahead. “

Q1FY25 Quarterly Result Announced for Mankind Pharma Ltd.

Pharmaceuticals company Mankind Pharma announced Q1FY25 results: Revenue from Operations at Rs 2,893 crore, up by 12% YoY Domestic revenue at Rs 2,634 crore, up 9% YoY; Exports at Rs 259 crore, up 62% YoY EBITDA margin of 23.7% with Adj. EBITDA margin of 25.2% and PAT margin of 18.8% Diluted EPS* of Rs 13.4, up by 10% YoY (FV Re.1) Rajeev Juneja – Vice Chairman & Managing Director, said: "We Witnessed a steady revenue growth of 12.2% Yoy with continued outperformance of 1.2x to IPM driven by a strong recovery in volume with Adjusted EBITDA margins of 25.2%. We are now the 2nd largest pharma company' by volume with an increase in market share of 20 bps YoY to 6.1%. Consistently expanding from mass market to specialty chronic leading to outperformance of 1.3x to IPM Chronic (with chronic share - 37%). BSV's super specialty business with high entry barrier portfolio and complex R&D; tech platform to add another layer of growth. In this quarter we In-licensed Inclisiran (Cardiac - lipid lowering) from Novartis, and Vonoprazan (Gastro) from Takeda"

Q4FY24 Quarterly & FY24 Annual Result Announced for Mankind Pharma Ltd.

Pharmaceuticals company Mankind Pharma announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from Operations at Rs 2,441 crore, up by 19% YoY Domestic revenue at Rs 2,174 crore, up 10% YoY; Exports at Rs 267 crore, up 230% YoY EBITDA margin of 24.3%, and PAT margin of 19.5% Diluted EPS of Rs 11.7, up by 65% YoY (FV Re.1) FY24 Financial Highlights: Revenue from Operations at Rs 10,335 crore, up by 18% Domestic revenue at Rs 9,522 crore, up by 13%; Exports at Rs 813 crore, up by 175% EBITDA margin of 24.7%, and PAT margin of 18.8% Diluted EPS of Rs 47.7, up by 49% (FV Re.1) Cash flow from operations of Rs 2,152 crore, up by 19% Net cash balance of Rs 3,260 crore as on 31st March 2024 Rajeev Juneja – Vice Chairman & Managing Director said, “This year, we have achieved a revenue milestone of Rs 10,000 crore. and added 3 more brand families worth over Rs 100 crore raising the total to 23. Our strong revenue growth of 18% with EBITDA and PAT margin of ~25% and ~19% respectively is supported by an increase in Chronic share to 36% and growth in Modern Trade of over 50%. We have further strengthened our chronic product portfolio with strategic in-house launches coupled with in-licensing of products like Symbicort – a globally renowned inhaler from Astra Zeneca. Multiple technology led business transformation projects implemented across functions to further enhance efficiency and productivity laying the foundation for our next phase of growth.”

Q3FY24 Quarterly & 9MFY24 Result Announced for Mankind Pharma Ltd.

Pharmaceuticals company Mankind Pharma announced Q3FY24 & 9MFY24 results: Q3FY24: Revenue from Operations at Rs 2,607 crore, 25% YoY growth Domestic revenue at Rs 2,400 crore, 20% YoY growth Export revenue at Rs 207 crore, 118% YoY growth EBITDA at Rs 611 crore, 39% YoY growth with a margin of 23.4% (up 240 bps YoY) PAT at Rs 460 crore, 55% YoY growth with a margin of 17.6% (up 350 bps YoY) Diluted EPS of Rs 11.3, 59% YoY growth (FV Re 1) 9MFY24: Revenue from Operations at Rs 7,894 crore, 18% YoY growth Domestic revenue at Rs 7,348 crore, 13% YoY growth Export revenue at Rs 546 crore, 154% YoY growth EBITDA at Rs 1,957 crore, 31% YoY growth with a margin of 24.8% (up 250 bps YoY) PAT at Rs 1,465 crore, 44% YoY growth with a margin of 18.6% (up 340 bps YoY) Diluted EPS of Rs 35.9, 44% YoY growth (FV Re 1) Cash flow from operations of Rs 1,636 crore, 23% YoY growth Net cash balance of Rs 2,756 crore as of 31st December 2023 Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma, said, “We are delighted to announce strong Q3 results with Domestic Growth of 20% YoY led by robust growth in Chronic, recovery in anti-infectives, and strong growth in modern trade and hospital sales. Our top 5 therapeutics by sales have outperformed the IPM by 1.5x. We have increased our market share in 18 out of the top 20 brands on both QoQ and YoY basis. These have resulted in a robust EBITDA growth of 39% YoY and PAT growth of 55% YoY in Q3. We continue to focus on improving cash flow from operations and optimising our working capital cycle.”